MBCL-47. OTOTOXICITY IN MEDULLOBLASTOMA SURVIVORS FOLLOWING PROTON RADIATION

ABSTRACT: Abstract

BACKGROUND

Radiotherapy to the cochlea and cisplatin exposure are both associated with hearing loss (HL) in medulloblastoma survivors. Here we report late outcomes in survivors with ≥1 year audiogram testing.

METHODS

Prospective medulloblastoma trial participants (clinicaltrials.gov: NCT01063114/NCT00105560) with ≥1 years of audiogram follow-up (FU, n=110 pts) comprised the study cohort. HL was graded using the SIOP-Boston ototoxicity scales (0-4) for each ear. Associations between grade 3 HL and mean cochlear radiation dose and cumulative cisplatin dose were evaluated. Target cisplatin dose was 450 mg/m2 but most patients did not receive full dose as dose reductions were used when ototoxicity was detected during chemotherapy.

FINDINGS

Median follow-up w

SUBMITTER: Byun J 

PROVIDER: S-EPMC6012575 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature